Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT versus PLEGINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT versus PLEGINE.
MELFIAT vs PLEGINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
Plegine (phendimetrazine) is a sympathomimetic amine that acts as an anorectic agent. It stimulates the hypothalamus to release norepinephrine and dopamine, thereby suppressing appetite. The exact mechanism is thought to involve the release of catecholamines from presynaptic nerve terminals in the lateral hypothalamic feeding center, leading to decreased food intake.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
25-50 mg orally once daily at bedtime, maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
Terminal elimination half-life: 4–8 hours (mean 6 hours). Clinical context: Steady-state achieved after 24–48 hours of repeated dosing.
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Renal: 40% unchanged; Hepatic metabolism: 60% (biliary/fecal elimination of metabolites).
Category C
Category C
Anorexiant
Anorexiant